Bayer Schering Pharma Ag

Edda Kraemer

Arwed Cleve

Gabriele Winter

Wolfgang Beckmann

Thomas Ginko

Evelin Amoulong

The present invention relates to crystalline forms of 11&#x3b2;-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17&#x3b1;-pregna-4,9-dien-3-one. The invention relates in particular to two crystalline ansolvate/anhydrate forms of this compound, polymorphs I and II. However, the present invention also relates to crystalline solvates, for example methanol and ethanol solvates of 11&#x3b2;-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17&#x3b1;-pregna-4,9-dien-3-one as precursors for preparing these two polymorphs I and II. Processes for preparing polymorph I by displacement crystallization or by trituration are described. Selection of the last solvent before formation of the ansolvate can be based on the differences in the purification behaviour of the individual solvates of 11&#x3b2;-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17&#x3b1;-pregna-4,9-dien-3-one. Polymorph I according to the invention is particularly suitable for the manufacture of medicinal products.

Growing community of inventors

Berlin, Germany

Edda Kraemer